Charles Schwab Investment Management Inc. Sells 9,097 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

Charles Schwab Investment Management Inc. decreased its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 0.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,122,531 shares of the biopharmaceutical company's stock after selling 9,097 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.54% of Royalty Pharma worth $97,204,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of RPRX. Adage Capital Partners GP L.L.C. raised its position in shares of Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after buying an additional 5,069,127 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Royalty Pharma by 270.4% in the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company's stock worth $112,788,000 after acquiring an additional 2,644,923 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Royalty Pharma in the fourth quarter worth approximately $41,959,000. AQR Capital Management LLC lifted its position in shares of Royalty Pharma by 187.0% during the 4th quarter. AQR Capital Management LLC now owns 1,903,676 shares of the biopharmaceutical company's stock worth $48,563,000 after buying an additional 1,240,384 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Royalty Pharma by 2,543.7% during the 1st quarter. Los Angeles Capital Management LLC now owns 1,081,128 shares of the biopharmaceutical company's stock worth $33,656,000 after buying an additional 1,040,234 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RPRX shares. Citigroup boosted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Wall Street Zen upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Morgan Stanley increased their price objective on shares of Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th.

Royalty Pharma Stock Down 0.4%

NASDAQ RPRX traded down $0.15 during trading on Friday, reaching $36.35. 2,936,706 shares of the company's stock were exchanged, compared to its average volume of 2,897,648. The firm has a market capitalization of $20.44 billion, a PE ratio of 21.01, a P/E/G ratio of 2.37 and a beta of 0.55. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $38.00. The company's fifty day simple moving average is $35.97 and its 200-day simple moving average is $33.75.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.10 by $0.04. The company had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. Sell-side analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Friday, August 15th. Royalty Pharma's dividend payout ratio (DPR) is currently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.